Document:

Exhibit 10.20

 

CONSULTING AGREEMENT

 

This Consulting Agreement (this “Agreement”) dated as of January 28, 2014 (the “Effective Date”) is made by and between Dr. Brian K. Kaspar (the “Consultant”) and BioLife Cell Bank, Inc., a Delaware corporation (the “Company”).

 

WHEREAS, the Company desires to retain the Consultant as an independent contractor to perform certain services; and

 

WHEREAS, the Consultant is willing to perform such services for the consideration and on the terms set forth in this Agreement;

 

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements herein contained, the parties hereby agree as follows:

 

1.      Scope of Services.

 

(a)     The Company hereby retains the Consultant and the Consultant hereby agrees to perform (i) service as Senior Scientific Advisor, of the Company; (ii) reasonable consulting and provision of information related to the Field (as defined in Exhibit A) as mutually deemed appropriate, and (iii) such other services for the Company as the Company and the Consultant may mutually agree from time to time (collectively, the “Services”). The Consultant shall report to the Chief Executive Officer or President of the Company.

 

(b)     The Consultant agrees to make himself available to render the Services at such time or times and location or locations as may be mutually agreed from time to time. The Consultant agrees to devote his best efforts to performing the Services. Notwithstanding any language to the contrary, the Parties recognize that Consultant’s primary responsibility remains at all times with his employer, the Research Institute at Nationwide Children’s Hospital (“RI”) and nothing in this Agreement is intended or shall be construed to create a conflict of interest, time, activity or commitment to RI. Subject to the RI Policies and Regulations (as defined in Section 4), the Consultant agrees that, at the request of the Company, the Consultant shall devote 10 working hours per calendar month to the performance of the Services.

 

2.      Compensation and Reimbursement.

 

(a)      For the performance of the Services, the Company shall:

 

(i)          pay the Consultant a fee at a monthly rate of $7,500.00 ($90,000.00 per annum) payable in arrears in equal biweekly installments (the “Consulting Compensation”) commencing on the date hereof. In the event that the Company requests that Consultant increase the number of hours that he performs on the Services, subject to the prior approval of RI, the Company and Consultant shall agree upon an appropriate increase to Consultant’s monthly rate; and

 

(ii)       the Company shall permit the Consultant to purchase 1,691,588 shares of the Company’s common stock, par value $0.0001, pursuant to a Restricted Stock Purchase Agreement (so called herein) in the form attached hereto as Exhibit B.

 

(b)       The Company shall promptly reimburse the Consultant for all reasonable expenses incurred by him in the performance of the Services in accordance with the policies and practices of the Company as in effect from time to time, provided such expenses are submitted to and approved for

 

1

 

reimbursement by the Company within six months of their occurrence, and provided further that any expense exceeding $1000 individually or $2500 in the aggregate in any two month period shall require the prior approval of the Chief Executive Officer or President of the Company.

 

(c)                  In the event that this Agreement is terminated during the Initial Term (as defined below) by the Company pursuant to Section 3(b)(xii) below or by the Consultant pursuant to Sections 3(b)(iii) or (iv) below, then the Company shall pay to the Consultant, within ten (10) business days after the date of such termination, an amount equal to the greater of (1) the total aggregate amount of the Consulting Compensation that would have been paid to Consultant over the remainder of the Initial Term or (2) $90,000.

 

(d)                 In the event that this Agreement is terminated after the Initial Term by the Company pursuant to Section 3(b)(xii) below or by the Consultant pursuant to Sections 3(b)(iii) or (iv) below, then the Company shall pay to the Consultant within ten (10) business days after the date of such termination the amount of $90,000.00. The Consultant shall not be entitled to any payment under this Section 2(d) in the event either the Company or me Consultant elects not to extend the term of this Agreement pursuant to Section 3(a) hereof.

 

(e)                  In the event that this Agreement is terminated during the Initial Term by the Company pursuant to Sections 3(b)(iii) through 3(b)(x) below (i.e., for cause as defined in Section 3(b) below), or by the Consultant pursuant to Section 3(b)(xi) below or is terminated by either me Company or the Consultant for any reason after the expiration of the Initial Term, then, except as otherwise provided in Section 2(d) of this Agreement, the Consultant will be entitled to receive solely that portion of Consulting Compensation payable in accordance with Section 2(a)(i) above accrued as of the effective date of such termination, and the Consultant shall not receive or be entitled to receive any further compensation hereunder following such termination except for any Payment due pursuant to Section 5(c) hereof for Post-Termination Services.

 

(f)                   In the event that this Agreement is terminated during the Initial Term pursuant to Section 3(b)(i) below, the written agreement contemplated by such Section 3(b)(i) shall set forth the compensation, if any, to which the Consultant shall be entitled upon such termination.

 

(g)                  The terms of this Section 2 shall survive termination of tins Agreement.

 

3. Term.

 

(a)      Unless earlier terminated pursuant to Section 3(b) below, tins Agreement shall have an Initial Term (so called herein) of four years commencing on the Effective Date and ending on the day (the “Scheduled Expiration Date”) immediately preceding the fourth anniversary of the Effective Date, at which time the term of tins Agreement shall automatically be extended for subsequent one year terms (each, an “Extension Term”), each until die next anniversary of the Scheduled Expiration Date, subject to either party providing written notice to the other party of its intent not to extend the term of this Agreement at least 60 days before the expiration of the then current Initial Term or Extension Term, as the case may be.

 

(b)       This Agreement will terminate or may be terminated as follows (with items (ii) through (x) being deemed “for cause”):

 

(i)                                                     by the written agreement of the Consultant and the Company;

 

2

 

(ii)                                                  [intentionally omitted];

 

(iii)                                               by written notice by the non-breaching party for a party’s breach of a material obligation under this Agreement, provided that the non-breaching party previously gave written notice to the other party of the alleged breach and thirty (30) days thereafter in which to cure the breach, during which 30-day period the breaching party did not cure the breach;

 

(iv)                                              by written notice by either the Consultant or the Company to the other party in the event that the other party enters a guilty plea or a plea of no-contest as to, is indicted for or is determined by a court of law to have committed, or is convicted of, a crime of dishonesty, fraud, embezzlement, theft, larceny or any crime of moral turpitude or any felony;

 

(v)                                                 by written notice by the Company in the event the Consultant is disabled (as evidenced by the Consultant’s inability to perform his obligations under this Agreement for a period of sixty (60) consecutive days);

 

(vi)                                              automatically upon the death of the Consultant;

 

(vii)                                           by written notice by the Company upon the appropriation or attempted appropriation of a material business opportunity of the Company by the Consultant, which would result in securing a personal profit to the Consultant;

 

(viii)                                        by written notice by the Company upon the theft or embezzlement by the Consultant of any of the real or personal property, tangible or intangible, of the Company or any of its affiliates;

 

(ix)                                              by written notice by the Company upon the commission of any act of fraud upon, or bad faith or willful misconduct toward, the Company or any of its affiliates by the Consultant;

 

(x)                                                 by written notice by the Company for any conduct by the Consultant constituting gross negligence or recklessness, as reasonably determined by the Company’s Board of Directors, that is or could have been materially injurious to the Company, a customer of the Company or any of the Company’s affiliates;

 

(xi)                                              by the Consultant for any or no reason whatsoever by providing written notice to the Company; or

 

(xii)                                           by the Company for any or no reason whatsoever by providing written notice to the Consultant.

 

(c)      No termination or expiration of this Agreement shall relieve the Consultant or the Company of any obligations hereunder which by their terms are intended to survive the termination of the Consultant’s association as a consultant with the Company, including but not limited to the obligations of Sections 2, 5, 6, 7, 8 and 9.

 

4.     Other Policies Applicable to Consultant. The Company acknowledges that the Consultant is an employee of, and a full-time member of the research faculty of RI and that his activities are subject to certain policies and regulations of RI, as well as certain contracts with RI, that relate to, among other things, the disclosure of proprietary information, the publication of research results, and/or the ownership of discoveries and inventions (“RI Policies and Regulations”). The Company acknowledges and agrees that the Consultant must adhere to the RI Policies and Regulations notwithstanding that they may be contrary to, or be in conflict with, the terms and conditions of this Agreement. The Company will not

 

3

 

deem the Consultant to be in breach of this Agreement, and the Company shall have no right to terminate this Agreement “for cause” as provided in Section 3, if the activity or omission committed by the Consultant that resulted in a breach of this Agreement or gave rise to the Company’s right to terminate the Agreement was in accordance with his obligation to comply with the RI Policies and Regulations.

 

5.      Non-Competition: Non-Solicitation.

 

(a) Subject to Section 4, so long as this Agreement continues in effect the Consultant shall not, without the prior approval of the Company, alone or as a partner, officer, director, consultant, employee, stockholder or otherwise, participate in any business, firm or corporation that develops any technology, process, method or products for, or directly relating to, the Field (a “Competing Company”) other than for the Company. The foregoing sentence, however, shall not be construed to prohibit, during the term of this Agreement: (i)the Consultant’s purchase on a national securities exchange or in the “over-the-counter” market of no more than two percent (2%) of the voting securities of a Competing Company listed on such exchange or publicly traded in such market; (ii) the Consultant from working for a Competing Company that has a number of divisions or business units, provided that the Consultant does not work for, or provide any Confidential Information (as defined in Section 7) to, the divisions or business units that research, develop, manufacture, license, sell, or otherwise provide any product or service directly relating to the Field; (iii)the Consultant from providing consulting services to a Competing Company subject to the policies and guidelines of the RL provided that the Company approves (in its sole discretion) each such consulting engagement in writing; (iv) during the term of this Agreement, the Consultant from pursuing research in me Field with RI funded by a governmental, commercial (not including a Competing Company), non-profit or academic sponsor(s) and publishing any results therefrom (subject to compliance with Section 7(f) hereof), provided, however, that nothing herein shall, without the Company’s prior written consent, permit Consultant to publish Company’s Confidential Information, and provided further that such research is not conducted with the intent of directly benefiting a Competing Company unless Consultant receives the Company’s prior written approval (in its sole discretion) therefor, or (v) the Consultant from at any time publishing materials that relate to the Field, provided, however, that nothing herein shall, without the Company’s prior written consent (in its sole discretion), permit Consultant to publish Company’s Confidential Information, Notwithstanding the foregoing, nothing in this Section 5(a) shall conflict with or supersede any of Consultant’s rights and responsibilities under Section 4 hereof. The limitations in this Section 5 shall apply solely to Consultant and nothing herein shall or is intended to restrict RI’s ability to engage in research in the Field with any funding source, or shall apply to any engagements of Consultant that predate the effective date of this Agreement

 

(b) During the Non-Competition Period, the Consultant shall not:

 

(i)         contact or solicit business from any customer of the Company for the purpose of attempting to sell, license or provide to or from such customer the same or similar products, services or technology as are currently provided by or to the Company or any product, service or technology that is similar to any such product, service or technology;

 

(ii)      solicit or take any other action which is intended to induce or encourage, or is reasonably likely to have the effect of inducing or encouraging, any employee or consultant of the Company to cease work for the Company;

 

(iii)         solicit or take any other action which is intended to induce or encourage, or is reasonably likely to have the effect of inducing or encouraging, any employee or consultant of

 

4

 

the Company to work for any Competing Company, without express prior written consent of the Board; or

 

(iv)        interfere, or attempt to interfere with, the relationship or prospective relationship of the Company with any person or entity that is or was a customer, client or supplier to the Company or to cause a customer, client or supplier to terminate an agreement with the Company.

 

(c)      As used in this Agreement, the term “Non-Competition Period” shall mean the period beginning with the date of this Agreement and continuing through the termination of this Agreement for any reason. The term “Post-Termination Period” shall mean the period beginning with the termination of this Agreement for any reason and continuing for 24 months thereafter. During the Post-Termination Period, the Consultant agrees to provide the Post-Termination Services (as defined below) to the Company in the maximum amount of up to ten (10) hours per month, and the Company agrees to retain the Consultant for such purposes; provided however, neither the Consultant’s performance of the Post-Termination Services nor anything in this Section 5 to the contrary will extend any non-competition period under this Agreement. For purposes of this Agreement, “Post-Termination Services” means to (i) advise and consult with the Company’s executive management and the Board with respect to the Company’s (a) technical, medical or scientific issues and problems relating to the design, development, production, sale or marketing of any products, technologies or services then currently developed, under development, produced, sold or marketed by the Company the (“Company Business”) and/or (b) the future anticipated direction of the Company Business as the Board may request, from time to time during the Post-Termination Period. The Company agrees to allow such services to be performed on weekends and during evening hours and to cooperate with the Consultant to the extent the Consultant secures other consulting or employment engagements during the Post-Termination Period. For providing the Post-Termination Services during the Post-Termination Period, the Company will in each calendar month during the Post-Termination Period that the Consultant provides the Post-Termination Services, pay the Consultant an amount equal $187.50 per hour (the “Payment”) for each hour (or on a prorated basis for each partial hour) of such services and reimburse Consultant for expenses as provided in Section 2(b) of this Agreement. The Payment is the Consultant’s sole compensation for providing the Post-Termination Services to the Company during the Post-Termination Period; provided, however, nothing contained in this Section 5(c) shall limit or offset amounts paid or to be paid to Consultant under Section 2 of this Agreement Notwithstanding the provisions of this Section 5(c), the vesting of the stock restricted under the Restricted Stock Purchase Agreement will cease upon termination of this Agreement and will not continue during the Post-Termination Period, except as otherwise provided in the Restricted Stock Purchase Agreement. In the event of a breach of the Consultant’s obligations set form in this Section 5(c), the Company will have the remedies provided herein and such other remedies as may be available to it under law or contract or at equity.

 

6.      Inventions and Discoveries. Subject to Section 4, during the term of this Agreement, the Consultant will promptly and simultaneously disclose to the Company and RI all inventions, discoveries, improvements, innovations, developments, concepts, designs, research methods and results, processes, formulae, compounds, products, works of authorship, trade secrets, know-how and creations (whether or not patentable or subject to copyright or trade secret protection, and whether or not reduced to tangible form, memorialized or reduced to practice) that the Consultant makes, conceives or reduces to practice, or has previously made, conceived or reduced to practice, either alone or jointly with others, that directly relate to or arise from Services performed by the Consultant for the Company (collectively, “Developments”). Ownership of such Developments, and any patent rights related thereto, shall reside with RI. If such Developments are not subject to the License Agreement by and between the Company

 

5

 

and RI for the scAAV9-SMN gene therapy product (the “License Agreement”), or not otherwise restricted by contract, RI grants the Company a Right of First Offer to negotiate a license for one or more of the Developments, and any patent rights related thereto, on terms and conditions similar to the License Agreement. In addition, RI shall grant the Company a Right of First Refusal on any Developments for a period of 120 days from the date of written notice from RI to the Company of its receipt of any offer to license or otherwise transfer or assign any Development.

 

7.      Confidential Information

 

(a)      As used in this Agreement, “Confidential Information” means all Developments made, conceived or reduced to practice under the this Agreement, trade secrets and confidential or proprietary information and other data or information (and any tangible representation thereof), whether prepared, conceived or developed by an employee of or consultant to the Company (including the Consultant in the provision of Services under the Agreement) or received by the Company from an outside source, which is in the possession of the Company (whether or not the property of the Company), which in any way relates to the present or future business of the Company, which is maintained in secrecy or confidence by the Company, and which might permit the Company or its customers to obtain a competitive advantage over competitors, who do not have access to such Developments made, conceived or reduced to practice under this Agreement, trade secrets, confidential or proprietary information or other data or information. Without limiting the generality of the foregoing, Confidential Information shall include:

 

(i)       any idea, improvement, invention, innovation, development, concept, technical data, design, formula, composition of matter, know-how, process, schematic, method, technique, activity, substrate, cellulosic material, enzyme, enzyme preparation process, catalyst, fermentation agent, fermentation reaction, bioreactor, bacteria or bacterial strain, microorganism, thermophilic organism, animal, plant, biological material (or a portion or fragment thereof), synthetic biological material, plasmid, compound, library, program, software, algorithm, subroutine, source code, object code, diagram, specification, drawing, manual, plan for new or revised services or products, compilation of information, derivative work, or work in process, or parts thereof, research or test data or results and any and all revisions and improvements relating to any of the foregoing (in each case whether or not reduced to tangible form, memorialized or reduced to practice); and

 

(ii)    the name of any customer, employee, prospective customer, sales agent, supplier or consultant, any sales plan, marketing material, plan or survey, business plan or opportunity, product or service development plan or specification, business proposal, financial record or information, or business record or other record or information relating to the present or proposed business of the Company.

 

The Company may from time to time have in its possession information which is claimed by others to be proprietary and which the Company has agreed to keep confidential. The Consultant hereby acknowledges that all such information shall be Confidential Information for purposes of this Agreement.

 

(b)      During the term of this Agreement and at all times thereafter, the Consultant will keep and hold all Confidential Information in strict confidence, and the Consultant will not use or disclose any of such Confidential Information without the prior written consent of the Company, except (i) as duly authorized by the Company and as may be necessary to perform the Consultant’s duties for the benefit of the Company or (ii) as otherwise required by applicable law; provided that the Consultant provides the Company with prompt notice of such requirement prior to compliance so that the Company may seek an appropriate protective order or waive the restriction on disclosure. If, in the absence of a protective order,

 

6

 

other legal remedy or the receipt of prior written consent by the Company, the Consultant is nonetheless, in the opinion of the Consultant’s legal counsel, legally compelled to disclose Confidential Information to any tribunal or else stand liable for contempt or suffer other censure or penalty, the Consultant may, without liability hereunder, disclose to such tribunal only that portion of the Confidential Information which such legal counsel advises is legally required to be disclosed, provided that the Consultant exercises commercially reasonable efforts to preserve the confidentiality of the Confidential Information including, without limitation, by cooperating with the Company to obtain (at the Company’s expense) an appropriate protective order or other reliable assurance that confidential treatment will be accorded the Confidential Information by such tribunal.

 

(c)        The Consultant’s obligations under Section 7(b) shall not apply to any Confidential Information that (i) is or becomes known to the general public under circumstances involving no breach by the Consultant of the terms of Section 7(b), (ii) is approved for public release by the Board of the Company or the Chief Executive Officer or President, (iii) is obtained by the Consultant, outside the context of the performance of the Services, from a third party who owes no obligation to the Company to maintain such information in confidence, or (iv) is any other information, technology or data provided to, or developed by, the Consultant without the use of Company resources or in the course of Consultant’s services for RJ or under the Clinical Trials Research Agreement.

 

(d)       Upon the termination of this Agreement or upon request of the Company, the Consultant shall promptly deliver to the Company all materials documenting, evidencing or embodying any Confidential Information, provided that Consultant may retain a copy of any such materials for archival purposes only.

 

(e)        The Consultant specifically agrees and acknowledges that the obligations of confidentiality described in this Section 7 are retroactive to the beginning of his performance of any services for the Company and shall apply to Confidential Information received by him at any time.

 

(f)         Subject to compliance with this Section 7, Consultant may publish the results of his research conducted for the Company hereunder. Consultant will provide the Company with a copy of any data, finding, result, article, abstract, manuscripts, presentation or other information intended for publication, at least thirty (30) days prior to submission of any intended publication. This will allow the Company time to review the material before it is made public, solely for the purposes of making any appropriate patent or other filings and verifying that no Confidential Information is disclosed. If the Company determines that the proposed publication contains patentable subject matter requiring protection, the Company may require, by providing written notice to Consultant prior to the expiration of such 30-day period, the delay of the submission for publication for a period of time not to exceed an additional sixty (60) days (unless otherwise agreed by Consultant and die Company in writing) after the expiration of such initial 30-day period for the purpose of allowing the pursuit of such protection. At the expiration of me thirty (30) day period if me Company has not provided written notice to the Consultant that me proposed publication contains patentable subject matter requiring protection, or at the expiration of such additional sixty (60) day period if the Company has timely notified Consultant that the proposed publication contains patentable subject matter requiring protection and the Company upon agreement of RI (or RI pursuant to the Clinical Trials Research Agreement) has filed for such patent protection, Consultant may proceed with submission for publication; provided, however, that in no event may Consultant publish any Confidential Information without the express prior written consent of the Company. Consultant shall acknowledge the Company’s role with respect to research sponsored by the Company in any publication contemplated by this Section 7(f).

 

7

 

8.      Remedies.

 

(a)       Each party may exercise all of its rights and remedies under this Agreement, at law and in equity, for any breach of this Agreement by the other.

 

(b)       The Consultant recognizes that in the event of a breach or threatened breach by the Consultant of any of Sections 5 through 7 of this Agreement, the Company may suffer irreparable harm, and the Consultant therefore agrees that, in addition to all other remedies available to the Company at law or in equity, the Company shall be entitled to apply for injunctive relief to restrain any such breach and to enforce the provisions hereof. The rights of the parties under this Section 8 will survive any termination of this Agreement.

 

9.      Miscellaneous.

 

(a)       The Consultant may use any ethical and lawful means necessary and appropriate to perform its obligations under this Agreement; provided, however, that in no event shall the Consultant take any action that would be adverse to the business interests of the Company or that may subject the Consultant or the Company to civil or criminal liability. The Consultant agrees to fully comply with all laws, rules and regulations applicable to its performance of the Services, and the Consultant covenants and agrees that he has no undisclosed interest that would conflict in any manner with the performance of the Services under this Agreement. In recognition of the independent contractor status of the Consultant, the Company agrees that, subject to the covenants contained in this Agreement, the Consultant may engage in additional activities and may allocate his time between the Consultant’s obligations under this Agreement and such other activities in any manner the Consultant deems appropriate, so long as the Consultant’s obligations under this Agreement are holly satisfied. Except as set forth in Section 2(b) hereof, the Consultant shall be responsible for all expenses incurred by the Consultant in furtherance of his provision of the Services. The Consultant will have the sole right to supervise, manage, control, and direct the performance of the details incident to the Consultant’s duties described in this Agreement.

 

(b)       The Consultant is and shall be an independent contractor with the sole right to supervise, manage, operate, control, and direct the performance of the details incident to the Consultant’s duties under this Agreement. Nothing contained in this Agreement shall be deemed or construed to create a partnership or joint venture, to create the relationships of an employer-employee or principal-agent, or to otherwise create any liability for or obligation of the Company whatsoever with respect to the indebtedness, liabilities, and obligations of the Consultant or any other party. The Consultant specifically understands and agrees that this Agreement shall not be deemed to grant or imply that the Consultant is authorized to sign, contract, deal, or otherwise act in the name of or on behalf of the Company, except as is expressly authorized in writing by the Company. The Company shall not maintain any insurance for the Consultant or its personnel, including, but not limited to, medical, dental, life, or disability insurance. The Consultant stipulates and agrees that he will not be eligible for any employment benefits from the Company. To the extent the Consultant employs others in providing services under this Agreement, the Consultant agrees to comply with all applicable workers’ compensation laws, to provide satisfactory assurances of such compliance to the Company on request, and to indemnify and hold harmless the Company from any liability or obligation in connection therewith. THE CONSULTANT SHALL NOT BE CONSIDERED UNDER THE PROVISIONS OF THIS AGREEMENT OR OTHERWISE AS HAVING THE STATUS OF AN EMPLOYEE OF THE COMPANY, OR AS BEING ENTITLED TO PARTICIPATE IN ANY LIFE, ACCIDENT OR HEALTH INSURANCE PLANS, PENSION, STOCK, BONUS, THRIFT OR PROFIT SHARING PLANS, WORKER’S COMPENSATION BENEFITS, VACATION/SICK LEAVE BENEFITS, OR ANY SIMILAR BENEFITS WHICH MAY BE

 

8

 

PROVIDED BY THE COMPANY FOR ITS EMPLOYEES, AND THE CONSULTANT HEREBY EXPRESSLY WAIVES ANY SUCH ENTITLEMENT, IF SUCH ENTITLEMENT EXISTS OR IS DEEMED TO EXIST.

 

(c)          The Consultant hereby acknowledges and agrees that, as an independent contractor, he is legally required to determine and pay its own estimated federal income taxes, FICA (including FICA-matching), and all applicable federal and state payroll, excise, workman’s compensation, and other withholdings owed, or claimed to be owed, by the Consultant by reason or arising out of the Consultant’s relationship with the Company pursuant to this Agreement, and the Consultant shall indemnify and hold the Company harmless from and against, and shall defend the Company against, any and all losses, damages, claims, costs, penalties, liabilities, and expenses (as incurred by the Company) arising out of or incurred because of, incident to, or otherwise with respect to any such taxes. The Consultant further acknowledges that the Company is legally obligated, and shall endeavor to issue timely, a yearly Form 1099 to the Consultant, and a Form 1096 to the Internal Revenue Service, reporting the full amount of fees paid to the Consultant during the reporting period.

 

(d)         This Agreement, together with the Exhibits hereto and the agreements referenced herein, constitute the entire agreement between the parties as to the subject matter hereof. No provision of this Agreement shall be waived, altered or canceled except in writing signed by the party against whom such waiver, alteration or cancellation is asserted. Any such waiver shall be limited to the particular instance and the particular time when and for which it is given.

 

(e)          Each party agrees that any suit, action or proceeding brought by such party against the other in connection with or arising from this Agreement (“Judicial Action”) shall be brought against any of the parties only in any United States federal or state court located in the State in which the respondent (defendant) is located at the time of the filing of the Judicial Action, and each of the parties hereto hereby consents to the exclusive jurisdiction of such courts in any such Judicial Action, waives any objection to venue laid therein and agrees that counterclaims and comparable actions against the party bringing the Judicial Action will not affect such venue. Process in any such Judicial Action proceeding may be served on any party anywhere in the world, whether within or without the State of venue. For purposes of this Section 9(e), a party’s location will be determined as follows: (i) for a party who is an individual, the State in which is located the party’s principal residence; and (ii) for a party who is an entity or organization, the State in which is located the party’s principal place of business, or, if, the party has more than one principal place of business, the State in which is located the party’s chief executive office.

 

(f)           This Agreement shall be binding upon and inure to the benefit of the parties and then-respective heirs, legal representatives, successors and permitted assigns. This Agreement and any rights or obligations hereunder may be assigned by the Company, in whole or in part, to any successor in connection with the sale of all or substantially all of the business of the Company, whether by asset sale or otherwise, and thereafter shall inure to the benefit of the purchaser or surviving company, as the case may be, in such transaction as fully as if it were the Company; and provided further, however, that any merger, reorganization, recapitalization or change of control or ownership of the Company shall not be deemed an assignment of this Agreement, even if this Agreement shall inure to the Company’s successor-in-interest with respect to any such transaction(s). The Consultant hereby acknowledges that the Company is, and may in the future be, affiliated with certain entities and that this Agreement shall extend to and protect all Confidential Information and Developments of all of the Company’s affiliated entities as fully as if such entities were referred to above in place of the Company and that each of them shall be entitled to enforce this Agreement with respect to its Confidential Information for its own benefit as fully as if it were referred to above in place of the Company. The Consultant may not assign this Agreement or any of

 

9

 

his rights or obligations hereunder to any person or entity without the express prior written consent of the Company, which consent may be granted or withheld by the Company in its sole discretion.

 

(g)        The Parties acknowledge and agree that RI is a third party beneficiary of this Agreement, as well as has certain obligations to the Company in this Agreement (See Section 6) inclusive of but not limited to Sections 4,5, and 6.

 

(h)       All notices and other communications hereunder shall be delivered or sent by commercial courier, facsimile, or registered or certified mail, return receipt requested, addressed to the party at the address herein set forth, or to such other address as such party may designate in writing to the other.

 

(i)           In the event that any provision of this Agreement shall be determined to be unenforceable by any court of competent jurisdiction by reason of its extending for too great a period of time or over too large a geographic area or over too great a range of activities, it shall be interpreted to extend only over the maximum period of time, geographic area or range of activities as to which it may be enforceable. If after application of the immediately preceding sentence, any provision of this Agreement shall be determined to be invalid, illegal or otherwise unenforceable by any court of competent jurisdiction, the validity, legality and enforceability of the other provisions of this Agreement shall not be affected thereby. Except as otherwise provided in this paragraph, any invalid, illegal or unenforceable provision of this Agreement shall be severable, and after any such severance, all other provisions hereof shall remain in full force and effect

 

IN WITNESS WHEREOF, the parties hereto have duly executed this Consulting Agreement as of the date first set forth above.

 

	
 
    	
BioLife Cell Bank Inc.
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
By: 
    	
/s/ John A. Carbona
    
	
 
    	
Name: John A. Carbona
    
	
 
    	
Title: Chief Executive   Officer
    
	
 
    	
 
    
	
 
    	
Address: 
    	
11970 N. Central   Expressway
    
	
 
    	
 
    	
Suite 260
    
	
 
    	
 
    	
Dallas, TX 75243
    
	
 
    	
 
    
	
 
    	
 
    
	
 
    	
/s/ Brian K. Kaspar,   Ph.D.
    
	
 
    	
Brian K. Kaspar, Ph.D.
    
	
 
    	
 
    
	
 
    	
Address: 
    	
Research Institute at   Nationwide
    
	
 
    	
 
    	
Children’s Hospital
    
	
 
    	
 
    	
700 Children’s Drive
    
	
 
    	
 
    	
Columbus, OH 43205
    
				

 

10

 

Reviewed and Acknowledged by

 

Research Institute at Nationwide Children’s Hospital

 

	
/s/ Amy Roscoe
    	
 
    
	
Amy Roscoe, Vice   President
    	
 
    
	
Research   Planning and Finance
    	
 
    
	
 
    	
 
    
	
Research   Institute at Nationwide Children’s Hospital
    	
 
    
	
700 Children’s   Drive
    	
 
    
	
Columbus, OH   43205
    	
 
    

 

11

 

Exhibit A

 

Field

 

The Consultant will provide reasonable consultation and provision of information related to the Field, defined as follows;

 

The field (the “Field”) is the research, development, and testing of therapies and treatment of spinal muscular atrophy.

 

Therapies and treatment applicable to the Field include gene therapy (the use of nucleic acids as pharmaceutical agents) but such gene therapy agents are not limited to the use of self-complementary adeno-associated virus (“scAAV”) as a vector to deliver nucleic acids to cells or the use of AAV serotype 9.

 

For avoidance of doubt, the Field will exclude the research, development, and testing relative to the OSU-jointly owned Patent Application # 61/695,824 and research, development and testing conducted by or on behalf of Milo Biotechnology IXC, an Ohio limited liability company, for the treatment of Becker muscular dystrophy and inclusion body myositis, using the rAAV1.CMV JiuFollistatin344 gene therapy product to deliver follistatin, a protein leading to increased muscle mass by its inhibition of myostatic. Furthermore, the Field will exclude the research, development, and testing conducted by or on behalf of Milo Biotechnology LLC for the treatment of other neurogenetic disorders using the rAAV1.CMV.huFollistatin344 gene therapy product. For avoidance of doubt, in addition to the above, me Consultant will provide reasonable consultation and provision of information gathered from his previous, current, and future knowledge related to the research, development, and testing of the scAAV9-SMN gene therapy product for the treatment of spinal muscular atrophy.

 

12

 

Exhibit B

 

Restricted Stock Purchase Agreement

 

(Attached hereto.)

 

13Exhibit 10.21

 

RESTRICTED STOCK PURCHASE AGREEMENT

 

This Restricted Stock Purchase Agreement (this “Agreement”‘) is made effective as of January 28, 2014, (the “Effective Date”) by and between BioLife Cell Bank, Inc., a Delaware corporation (the “Company”), and Dr. Brian K. Kaspar (“Purchaser”).

 

Now, therefore, in consideration of the mutual covenants and representations herein set forth, the Company and Purchaser agree as follows:

 

1.     Purchase and Sale of Stock. Subject to the terms and conditions of this Agreement, the Company hereby agrees to sell to Purchaser and Purchaser agrees to purchase from the Company 1,691,588 shares (the “Stock”) of the Company’s common stock, par value $0.0001 per share, at a price of $0.0001 per share for an aggregate purchase price of $169.16 (the “Purchase Price”). The purchase price for the Stock shall be paid by Purchaser to the Company in the form of cash, check or wire transfer.

 

2.     Closing. The purchase and sale of the Stock shall occur contemporaneous upon the execution of this Agreement by both parties hereto. At the closing, Purchaser shall deliver to the Company payment equal to the Purchase Price and the Company will issue and deliver to Purchaser certificate(s) representing the Stock registered in the name of Purchaser.

 

3.     Purchase Option. The Stock shall be subject to the right and option of the Company to repurchase the Stock as set forth in this section 3.

 

(a)   Termination of Engagement. Subject to the terms of Sections 3(b) and 3(e) of this Agreement, in the event Purchaser shall cease to serve as a consultant or contractor to the Company (including a parent or subsidiary of the Company) because of the termination of that certain Consulting Agreement (as same may be amended from time to time, the “Consulting Agreement”) of even date herewith between the Company and the Purchaser by the Company pursuant to Sections 3(b)(iii) through 3(b)(x) of the Consulting Agreement or by Purchaser pursuant to Section 3(b)(xi) of the Consulting Agreement (collectively, a “Termination”), a purchase option (“Purchase Option”) shall come into effect as set forth in this section 3(a). Following such a Termination (but subject to the terms of Sections 3(b) and 3(e) of this Agreement), the Company shall have the right to purchase from Purchaser, at the purchase price per share equal to the per share price paid by Purchaser as set forth in section 1 above (“Purchase Option Price”), a portion of the Stock, such portion to be determined in accordance with section 3(b) of this Agreement.

 

(b)   Effective the date of this Agreement and in compliance with all of the terms and conditions hereof, twenty-five percent (25%) of the shares of the Stock (being 422,897 shares) shall be free of the Purchase Option. Thereafter,

 

(i)            The Purchase Option shall lapse as to an additional twenty-five percent (25%) (being 422,897 shares) of the Stock on the day before the second anniversary date of the Effective Date (the “Two Year Anniversary”); and

 

(ii)           Following the Two Year Anniversary, the Purchase Option shall lapse as to an additional twenty-five percent (25%) (being 422,897 shares) of the Stock on the

 

1

 

day before each successive anniversary of the Two Year Anniversary until all Stock is free of the Purchase Option, being on the day before the fourth anniversary date of the Effective Date.

 

(c)   Notice of Intent to Purchase. Within 90 days following a Termination, the Company shall notify Purchaser (or his legal representative if the Termination is by reason of Purchaser’s death or disability) by written notice delivered or mailed as provided in section 10(c) as to whether it wishes to purchase the Stock pursuant to exercise of the Purchase Option. If the Company (or its parent, subsidiary or successor) elects to purchase the Stock hereunder, it shall set a date for the closing of the transaction at a place specified by the Company not later than 15 days from the date of such notice. At such closing, the Company (or its parent, subsidiary or successor) shall tender payment for the Stock and the certificates representing the Stock so purchased shall be transferred to the Company and shall be canceled. If at such closing, Purchaser does not execute an assignment of the Stock to the Company, Purchaser hereby expressly authorizes and directs the Secretary (or his designee) or the transfer agent of the Company for and on behalf of Purchaser as his lawful attorney-in-fact to complete, date, and deliver to the Company the attached assignment separate from the certificate and thereby to so transfer the Stock as to which the Purchase Option has been exercised from Purchaser to the Company. The Purchase Option Price may be payable, at the option of the Company, in cash, by check, or by cancellation of indebtedness owed to the Company by Purchaser, or any combination thereof.

 

(d)   The Company may, in its sole and unfettered discretion, assign its rights and delegate its duties under this Agreement, including without limitation the Purchase Option, to its parent or any subsidiary of the Company or to any person acquiring all or substantially all of the assets of the Company.

 

(e)   Notwithstanding anything to the contrary contained in this Agreement, if the Consulting Agreement is terminated by the Company pursuant to Section 3(b)(xii) thereof or by the Purchaser pursuant to Sections 3(b)(iii) or (iv) thereof, the Purchase Option shall lapse as to any Stock still subject thereto automatically on such termination. Thereafter, no shares of Stock held by Purchaser shall be subject to the Purchase Option.

 

4.     Stock Splits, Change in Control.

 

(a)           If, from time to time during the term of this Agreement, there is any stock dividend or liquidating dividend of cash and/or property, stock split, or other change in the character or amount of any of the outstanding securities of the Company, then, in such event, any and all new, substituted or additional securities or other property to which Purchaser is entitled by reason of his ownership of Stock shall be immediately subject to this Agreement and be included in the word “Stock” for all purposes with the same force and effect as the shares of Stock presently subject to this Agreement. While the aggregate Purchase Option Price shall remain the same after each such event, the Purchase Option Price per share of Stock upon execution of the Purchase Option shall be appropriately adjusted.

 

2

 

(b)           If, during the term of this Agreement, there is a Change in Control of the Company, the Purchase Option shall lapse as to any Stock still subject thereto on the date of consummation of such Change in Control. Thereafter, no shares of Stock held by Purchaser shall be subject to the Purchase Option. For purposes of this Agreement, “Change in Control” shall mean:

 

(i)            a sale of all or substantially all of the assets of the Company; or

 

(ii)           a merger, share-exchange, reverse merger or consolidation of the Company in which the shareholders of the Company own, as a result of the transaction, less than 50% of the outstanding securities of the surviving corporation; or

 

(iii)         a transaction or a series of related transactions to which the Company is a party in which there is a sale of outstanding securities representing more than 50% of the voting power of the Company.

 

5.     Legends. All certificates representing any shares of Stock of the Company subject to the provisions of this Agreement shall have endorsed thereon legends in substantially the following form:

 

“THE SHARES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN PURCHASE OPTION RIGHTS AS SET FORTH IN AN AGREEMENT BETWEEN THE CORPORATION AND THE REGISTERED HOLDER, A COPY OF WHICH IS ON FILE AT THE PRINCIPAL OFFICE OF THE CORPORATION.”

 

“THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER SAID ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE CORPORATION THAT SUCH REGISTRATION IS NOT REQUIRED.”

 

6.     Investment Intent and Risk Factors. In purchasing the Stock, Purchaser acknowledges and represents that Purchaser has had an opportunity to discuss the business prospects and business plan of the Company with the officers and directors of the Company. Purchaser further acknowledges that the Stock is highly speculative and involves a high degree of risk, and that the Stock has not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be sold or otherwise disposed of except pursuant to an effective Registration Statement filed under the Act or pursuant to an exemption from said Act. Purchaser hereby acknowledges that the Company is under no obligation to register the Stock under the Act on behalf of Purchaser. Purchaser warrants and represents to the Company that he is acquiring the Stock for investment and not with a view to or for sale in connection with any distribution of said Stock or with any present intention of distributing or selling said Stock and he does not presently have reason to anticipate any change in circumstances or any particular occasion or event which would cause him to sell said Stock. By execution of this Restricted Stock Purchase Agreement, Purchaser hereby expressly confirms the investment representations

 

3

 

set forth in Exhibit A attached hereto and incorporated herein by this reference, and the Company hereby expressly agrees to the Company’s obligations set forth in said Exhibit A.

 

7.     Delivery of Certificate. To ensure the availability for delivery of Purchaser’s Stock upon exercise of the Purchase Option herein provided for, Purchaser hereby delivers to and deposits with the Secretary of the Company the Stock Assignment attached hereto as Exhibit B, duly endorsed (with the assignee, date, number of shares and certificate number(s) left blank), together with the certificate or certificates evidencing the Stock; provided, however, such Stock Assignment may be utilized by the Company only in accordance with Section 3(c) of this Agreement and only if at the closing anticipated by said Section 3(c) Purchaser does not execute an assignment of the Stock to the Company. Upon written request of Purchaser after each successive period from the Effective Date set forth in Section 3 of this Agreement, unless the Purchase Option has been exercised, the Company will deliver to Purchaser, within 15 days after such request, a certificate or certificates representing so many shares of the Stock as are not then subject to the Purchase Option. Within 15 days from receipt of the Company’s notice of intent to purchase following a Termination and upon closing of the repurchase transaction as provided in Section 3 of this Agreement, the Company will deliver to Purchaser a certificate or certificates representing the aggregate number of shares of Stock sold and issued pursuant to this Agreement and not purchased by the Company or its assignees pursuant to exercise of the Purchase Option. If the Company fails to timely deliver to Purchaser its notice of intent to purchase following a Termination, then the Company will deliver to Purchaser the aforementioned certificate or certificates within 120 days from the date of Termination.

 

8.     Miscellaneous.

 

(a)           Subject to the provisions hereof, Purchaser shall, during the term of this Agreement, be entitled to exercise all rights and privileges of a shareholder of the Company with respect to the Stock.

 

(b)           The parties hereto agree to execute such further instruments and to take such further action as may reasonably be necessary to carry out the intent of this Agreement.

 

(c)           Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon personal delivery or upon deposit in the United States Mail, by registered or certified mail with postage and fees prepaid, addressed to Purchaser at his address shown on the Company’s records and to the Company at the address of its principal corporate offices (Attention: Chief Executive Officer) or at such other address as such party may designate by 10 days’ advance written notice to the other party hereto. Purchaser hereby represents that the address set forth below under his signature is his current residential address.

 

(d)           The Company may assign its rights and delegate its duties under sections 3 and 5 hereof. This Agreement shall inure to the benefit of the successors and assigns of the Company and Purchaser and be binding upon the Company and its successors and assigns and, subject to the restrictions on transfer herein set forth, be binding upon Purchaser, his heirs, executors, administrators, successors and assigns.

 

4

 

9.     Arbitration. Any controversy or claim arising out of or relating to this Agreement, or violation of this Agreement, shall be settled by arbitration in accordance with the rules of JAMS, and judgment rendered by the arbitrator may be entered in any court having jurisdiction thereover. The arbitration shall be conducted in Dallas, Texas unless otherwise agreed by the parties thereto. The arbitrator shall be deemed to possess the power to issue mandatory orders and restraining orders in connection with such arbitration; provided, however, that nothing in this Section 11 shall be construed as to deny the Company the right and power to seek and obtain injunctive relief in a court of competent jurisdiction for any breach or threatened breach of Purchaser’s covenants and obligations contained in this Agreement.

 

10.  Representation re Exhibits; Obligations of the Company re Exhibit A. Purchaser hereby expressly represents that Purchaser has reviewed the attached Exhibits A and B and agrees to be bound by the terms thereof. The Company expressly represents that the Company has reviewed Section 7 of Exhibit A and agrees to be bound by the terms of said Section 7 of Exhibit A.

 

11.          Company’s Representations about the Stock. The Company represents and warrants to Purchaser as follows:

 

(a)           The authorized capitalization of the Company consists solely of 70,000,000 shares, of which 50,000,000 are Common Stock, par value $0.0001 per share, and 20,000,000 are Preferred Stock, par value $0.0001 per share.

 

(b)           As of the Effective Date but prior to the issuance of the Stock to Purchaser, 5,356,694 shares of the Common Stock are issued and outstanding and no shares of the Preferred Stock are issued and outstanding.

 

(c)           The Stock, when issued, will be validly issued, fully paid and non-assessable, and will not have been issued in violation of the preemptive or other rights of any person.

 

5

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the Effective Date.

 

	
BIOLIFE CELL   BANK, INC.,
    	
PURCHASER
    
	
a Delaware   Corporation
    	
Dr. Brian   K. Kaspar
    
	
 
    	
 
    
	
 
    	
/s/ Brian K. Kaspar
    
	
By:
    	
/s/ John A.   Carbona
    	
 
    	
 
    
	
 
    	
John A. Carbona,   CEO
    	
 
    	
 
    
	
 
    	
 
    
	
ADDRESS:
    	
ADDRESS:
    
	
 
    	
 
    
	
11970 N. Central   Expressway, Suite 260
    	
7883 Calverton   Square
    
	
Dallas, Texas   75243
    	
New Albany, Ohio   43054
    

 

6

 

EXHIBIT A

INVESTMENT REPRESENTATIONS;

INDEMNIFICATION OBLIGATIONS OF THE COMPANY

 

This Exhibit A is an exhibit to, and is incorporated into and made a part of, the attached Restricted Stock Purchase Agreement, dated as of January 28, 2014 (the “Restricted Stock Purchase Agreement”), by and between BioLife Cell Bank, Inc., a Delaware corporation, and Dr. Brian Kaspar. Capitalized terms used herein but not defined shall have the meanings ascribed to them in the Restricted Stock Purchase Agreement. In connection with the purchase of the Stock Purchaser hereby agrees, represents and warrants to the Company, and the Company agrees, as follows:

 

1.             Purchase Entirely for Own Account.

 

Purchaser represents and warrants that Purchaser is purchasing the Stock solely for Purchaser’s own account for investment and not with a view to or for sale or distribution of the Stock or any portion thereof and not with any present intention of selling, offering to sell or otherwise disposing of or distributing the Stock or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act of 1933, as amended (the “Act”). Purchaser also represents that the entire legal and beneficial interest of the Stock Purchaser is purchasing is being purchased for, and will be held for the account of, Purchaser only and neither in whole nor in part for any other person.

 

2.     Residence.

 

Purchaser represents and warrants that Purchaser’s principal residence is within the state set forth below Purchaser’s signature on the Restricted Stock Purchase Agreement.

 

3.     Information Concerning Company.

 

Purchaser represents and warrants that Purchaser has heretofore discussed the Company and its plans, operations and financial condition with its officers and that Purchaser has heretofore received all such information as Purchaser deems necessary and appropriate to enable Purchaser to evaluate the financial risk inherent in making an investment in the Stock, and Purchaser further represents and warrants that Purchaser has received satisfactory and complete information concerning the business and financial condition of the Company in response to all inquiries in respect thereof. Purchaser acknowledges that, as of the Effective Date, the Company intends to consummate a capital raise through the establishment and issuance of shares of Class B Common Stock (so called herein), in connection with which the Stock acquired by Purchaser hereunder will (assuming such capital raise is consummated) be reclassified as Class A Common Stock (so called herein); Purchaser further acknowledges that the Class B Common Stock will be entitled to certain liquidation preferences in priority over the Class A Common Stock.

 

4.     Economic Risk.

 

Purchaser represents and warrants that Purchaser realizes that Purchaser’s purchase of the Stock will be a highly speculative investment and that Purchaser is able, without impairing

 

7

 

Purchaser’s financial condition, to hold the Stock for an indefinite period of time and to suffer a complete loss on Purchaser’s investment.

 

5.     Sophistication; Accreditation.

 

Purchaser is a person who either alone or with his purchaser representative(s) has sufficient knowledge and experience in financial and business matters to be capable of evaluating the merits and risks of an investment in the Company. Purchaser is an “accredited investor” within the meaning of Rule 501(a)(4) of Regulation D as promulgated under the Act by virtue of the fact that he is a director of the Company.

 

6.     Restricted Stock; Disposition Under Rule 144.

 

(a)           Purchaser represents and warrants that the Company has hereby disclosed to Purchaser in writing:

 

(i)            the sale of the Stock which Purchaser is purchasing has not been registered under the Act, and the Stock must be held indefinitely unless subsequently registered under the Act or unless an exemption from such registration is available;

 

(ii)           the share certificate(s) representing the Stock will be stamped with the legends specified in the Restricted Stock Purchase Agreement; and

 

(iii)          the Company will make a notation in its records of the aforementioned Purchase Option and legends.

 

(b)   Purchaser represents and warrants that Purchaser understands that the shares of Stock are restricted stock within the meaning of Rule 144 promulgated under the Act; that the exemption from registration under Rule 144 will not be available unless (i) Purchaser has held such shares for the applicable period required by Rule 144, (ii) a public trading market then exists for the Common Stock of the Company, (iii) adequate information concerning the Company is then available to the public, and (iv) all other applicable terms and conditions of Rule 144 are complied with; and that any sale of the Stock may be made by Purchaser only in limited amounts in accordance with such terms and conditions.

 

7.     Tax Disclosure; Company’s Covenants of Indemnification.

 

(a)           Purchaser represents and warrants that Purchaser has reviewed and understands the following information regarding potential tax liability resulting from the purchase of the Stock.

 

(b)           The common stock issued in this transaction has been valued in good faith by the board of directors of the Company for not less than fair market value and is being sold to Purchaser for such amount. The Company believes this valuation represents a fair attempt at reaching an accurate appraisal of its worth. However, it is possible that with the benefit of hindsight, the Internal Revenue Service would successfully assert that the value of the common shares is substantially greater than so determined.

 

8

 

(c)           If the Internal Revenue Service were to succeed in a tax determination that the common stock received had value greater than that upon which the transaction was based, the additional value would constitute ordinary income to Purchaser as of the date of its receipt by Purchaser. The additional taxes (and interest) due would be payable by Purchaser. In certain cases, the Internal Revenue Service could have up to six years from the due date for filing the return (or the actual filing date of the return if filed thereafter) within which to assess Purchaser for the additional tax and interest, which would then be due. The events described in these clauses (b) and (c) will hereinafter be referred to collectively as an ‘‘Adverse Tax Event.”

 

(d)   The Company would have the benefit, in any such transaction, if a determination was made prior to the three year statute of limitations period affecting the Company, of an increase in its deduction for compensation paid, which would offset its operating profits, or, if not profitable, would create net operating loss carry forward arising from operations in that year.

 

(e)           Notwithstanding the terms of this Section 7, the Company covenants and agrees to indemnify, defend and hold harmless Purchaser and his heirs, executors, administrators, successors and assigns (collectively, the “Other Indemnified Parties”) from and against all taxes, interest, fines, penalties and costs and expenses (including, without limitation, reasonable attorneys’ fees, court costs and costs of appeal) that Purchaser or any of the Other Indemnified Parties suffer or incur arising out of, in connection with or related to an Adverse Tax Event. Purchaser (or the Other Indemnified Parties as the case may be) will promptly notify the Company in writing of any notice or other communication received and pertaining to a possible Adverse Tax Event; provided, however, that the failure to so notify the Company will not relieve the Company from liability under this Agreement with respect to such claim for indemnification unless the Company is materially prejudiced as result of such failure to give prompt notice. If the Company declines or fails to assume the defense of such Adverse Tax Event or fails to employ counsel reasonably satisfactory to Purchaser (or the Other Indemnified Parties as the case may be), in each case within thirty (30) days after receipt of the notice, then Purchaser and any of the Other Indemnified Parties may employ counsel to represent or defend them in regard to the Adverse Tax Event, and the Company will pay the reasonable fees and disbursements of such counsel as incurred. Purchaser (and the Other Indemnified Parties as the case may be) will have the right to participate in defense of the Adverse Tax Event and to retain their own counsel at such person’s own expense. The Company will at all times keep the Purchaser (and the Other Indemnified Parties as the case may be) reasonably apprised of the status of the defense of any Adverse Tax Event, and the Company and Purchaser (and the Other Indemnified Parties as the case may be) will cooperate in good faith with each other with respect to the defense of any such matter. Neither the Company nor the Purchaser (nor any of the Other Indemnified Parties as the case may be) may settle or compromise any claim or consent to the entry of any judgment with respect to which indemnification is being sought hereunder without the prior written consent of the other, unless (i) the Company fails to assume and maintain the defense of such claim or (ii) such settlement, compromise or consent includes an unconditional release of Purchaser (and the Other Indemnified Parties as the case may be) from all liability and obligations to pay any amounts arising out of the Adverse Tax Event. The terms of Sections 7(b), (c) and (e) shall survive for a period of six (6) years after the due date for filing Purchaser’s federal income tax return (Form 1040) for the tax year in which the Stock was issued to Purchaser.

 

9

 

EXHIBIT B

ASSIGNMENT SEPARATE FROM CERTIFICATE

 

FOR VALUE RECEIVED and pursuant to that certain Restricted Stock Purchase Agreement dated as of January 28, 2014, Dr. Brian Kaspar hereby sells, assigns and transfers unto                     ,                      shares of the common stock, par value $0.0001 of BioLife Cell Bank, Inc., a Delaware corporation, standing in the undersigned’s name on the books of said corporation represented by certificate no(s).                     , and does hereby irrevocably constitute and appoint the corporate secretary of said corporation as attorney to transfer the said stock on the books of the said corporation with full power of substitution in the premises.

 

Dated:                             , 2014

 

 

	
Signature:
    	
 
    	
 
    

 

10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]